Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant catumaxomab versus surgery alone after curative resection of gastric adenocarcinoma
2005-005945-20Phase 2Completed
- Sponsor
- Fresenius
- Start
- Mar 2006
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of catumaxomab in gastric adenocarcinoma (2 arms), sponsored by Fresenius. Primary endpoint: Frequency, relationship and seriousness of adverse events. Started Mar 2006; status: completed.
02
Drugs
catumaxomab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2005-005945-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005945-20.